RHB -104 Emerging Drug Insight

“RHB -104 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about RHB-104 for Crohn’s disease (CD) in the 7MM. A detailed picture of the RHB-104 for Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the RHB-104 for Crohn’s disease (CD). The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RHB-104 market forecast, analysis for Crohn’s disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s disease (CD).

Drug Summary

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial, and anti-inflammatory properties, developed by RedHill Biopharma. The development of RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium Avium subspecies Paratuberculosis (MAP) infection in susceptible patients rather than being an autoimmune disease.

RHB-104 is a patent-protected combination of 3 antibiotics (clarithromycin, clofazimine, and rifabutin) in a single oral capsule with potent intracellular, antimycobacterial, and anti-inflammatory properties. The development of RHB-104 is consistent with the growing awareness of the possibility that a bacterially-induced dysregulated immune system may contribute to the pathogenesis of various autoimmune diseases of unknown etiology. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori. RHB-104 is being developed for Crohn’s disease and Multiple sclerosis.

 The company has completed two Phase III trials (NCT03009396 and NCT01951326). RedHill announced in October 2019 the full Week 52 results from its global first Phase III clinical study of RHB-104 in Crohn’s disease (MAP US). The study was designed to evaluate the safety and efficacy of fixed-dose RHB-104 in patients with moderately to severely active Crohn's disease.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the RHB-104 description, mechanism of action, dosage and administration, research and development activities in Crohn’s disease (CD).
•  Elaborated details on RHB-104 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the RHB-104 research and development activity in Crohn’s disease (CD) in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around RHB-104.
•  The report contains forecasted sales of RHB-104 for Crohn’s disease (CD) till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Crohn’s disease (CD).
•  The report also features the SWOT analysis with analyst views for RHB-104 in Crohn’s disease (CD).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RHB-104 Analytical Perspective by DelveInsight

• In-depth RHB-104 Market Assessment

This report provides a detailed market assessment of RHB-104 in Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• RHB-104 Clinical Assessment

The report provides the clinical trials information of RHB-104 in Crohn’s disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Crohn’s disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RHB-104 dominance.
•  Other emerging products for Crohn’s disease (CD) are expected to give tough market competition to RHB-104 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RHB-104 in Crohn’s disease (CD).
•  Our in-depth analysis of the forecasted sales data of RHB-104 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RHB-104 in Crohn’s disease (CD).

Key Questions

•  What is the product type, route of administration and mechanism of action of RHB-104?
•  What is the clinical trial status of the study related to RHB-104 in Crohn’s disease (CD) and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RHB-104 development?
•  What are the key designations that have been granted to RHB-104 for Crohn’s disease (CD)?
•  What is the forecasted market scenario of RHB-104 for Crohn’s disease (CD)?
•  What are the forecasted sales of RHB-104 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Crohn’s disease (CD) and how are they giving competition to RHB-104 for Crohn’s disease (CD)?

 Which are the late-stage emerging therapies under development for the treatment of Crohn’s disease (CD)?